Controversies  	Controversies  	 NNS	O
around  	around  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
advanced  	advanced  	 JJ	O
non-small  	non-small  	 JJ	B-NP
cell  	cell  	 NN	I-NP
lung  	lung  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
First  	First  	 JJ	I-NP
line  	line  	 NN	I-NP
combination  	combination  	 NN	I-NP
chemotherapy  	chemotherapy  	 NNS	I-NP
( 	( 	 -LRB-	O
CT 	CT 	 NNP	B-NP
)  	)  	 -RRB-	O
using  	using  	 VBG	O
platinum-based  	platinum-based  	 JJ	O
doublets  	doublets  	 NN	O
is  	is  	 VBZ	O
established  	established  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
standard  	standard  	 NN	O
of  	of  	 IN	O
care  	care  	 NN	O
for  	for  	 IN	O
advanced  	advanced  	 JJ	O
non-small  	non-small  	 JJ	B-NP
cell  	cell  	 NN	I-NP
lung  	lung  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
( 	( 	 -LRB-	O
NSCLC 	NSCLC 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Nevertheless 	Nevertheless 	 RB	O
,  	,  	 ,	O
no  	no  	 DT	O
significant  	significant  	 JJ	O
advances  	advances  	 NNS	O
have  	have  	 VBP	O
been  	been  	 VBN	O
recorded  	recorded  	 VBN	O
during  	during  	 IN	O
the  	the  	 DT	O
last  	last  	 JJ	O
years  	years  	 NNS	O
in  	in  	 IN	O
this  	this  	 DT	O
field 	field 	 NN	O
.  	.  	 .	O
Therefore 	Therefore 	 RB	O
,  	,  	 ,	O
there  	there  	 EX	O
is  	is  	 VBZ	O
a  	a  	 DT	O
wide  	wide  	 JJ	O
consensus  	consensus  	 NN	O
among  	among  	 IN	O
physicians  	physicians  	 NNS	O
that  	that  	 IN	O
a  	a  	 DT	O
plateau  	plateau  	 NN	O
has  	has  	 VBZ	O
already  	already  	 RB	O
been  	been  	 VBN	O
reached  	reached  	 VBN	O
with  	with  	 IN	O
this  	this  	 DT	O
strategy 	strategy 	 NN	O
.  	.  	 .	O
Targeted  	Targeted  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
using  	using  	 VBG	O
tyrosine-kinase  	tyrosine-kinase  	 JJ	B-NP
inhibitors  	inhibitors  	 NNS	I-NP
( 	( 	 -LRB-	O
TKIs 	TKIs 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
emerged  	emerged  	 VBD	O
as  	as  	 IN	O
a  	a  	 DT	O
new  	new  	 JJ	O
field  	field  	 NN	O
of  	of  	 IN	O
development  	development  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
NSCLC  	NSCLC  	 NNP	B-NP
therapeutics 	therapeutics 	 NN	I-NP
.  	.  	 .	O
Recently 	Recently 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
results  	results  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
trials  	trials  	 NNS	O
testing  	testing  	 VBG	B-NP
antibodies  	antibodies  	 NNS	I-NP
against  	against  	 IN	O
vascular  	vascular  	 JJ	B-NP
endothelial  	endothelial  	 JJ	I-NP
growth  	growth  	 NN	I-NP
factor-VEGF  	factor-VEGF  	 NNS	I-NP
( 	( 	 -LRB-	O
bevacizumab 	bevacizumab 	 LS	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
epidermal  	epidermal  	 JJ	B-NP
growth  	growth  	 NN	I-NP
factor  	factor  	 NN	I-NP
receptor-EGFR  	receptor-EGFR  	 NNS	I-NP
( 	( 	 -LRB-	O
cetuximab 	cetuximab 	 LS	B-NP
)  	)  	 -RRB-	O
challenged  	challenged  	 VBD	O
the  	the  	 DT	O
paradigm  	paradigm  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
platinum  	platinum  	 NN	O
doublets  	doublets  	 NN	O
as  	as  	 IN	O
a  	a  	 DT	O
gold  	gold  	 NN	O
standard  	standard  	 NN	O
in  	in  	 IN	O
advanced  	advanced  	 JJ	O
NSCLC 	NSCLC 	 NNP	B-NP
.  	.  	 .	O
Their  	Their  	 PRP$	O
appearance  	appearance  	 NN	O
was  	was  	 VBD	O
enthusiastically  	enthusiastically  	 RB	O
commended  	commended  	 VB	O
both  	both  	 DT	O
by  	by  	 IN	O
patients  	patients  	 NNS	O
and  	and  	 CC	O
the  	the  	 DT	O
oncological  	oncological  	 JJ	B-NP
community 	community 	 NN	I-NP
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
all  	all  	 DT	O
medical  	medical  	 JJ	B-NP
oncologists  	oncologists  	 NNS	I-NP
have  	have  	 VBP	O
the  	the  	 DT	O
responsibility  	responsibility  	 NN	O
to  	to  	 TO	O
carefully  	carefully  	 RB	O
analyze  	analyze  	 VB	O
the  	the  	 DT	O
real  	real  	 JJ	O
benefits  	benefits  	 NNS	O
of  	of  	 IN	O
these  	these  	 DT	O
new  	new  	 JJ	O
agents 	agents 	 NNS	O
,  	,  	 ,	O
to  	to  	 TO	O
balance  	balance  	 VB	O
the  	the  	 DT	O
advantages  	advantages  	 NNS	O
against  	against  	 IN	O
the  	the  	 DT	O
implicit  	implicit  	 JJ	O
risks  	risks  	 NNS	O
of  	of  	 IN	O
therapy  	therapy  	 NN	O
and  	and  	 CC	O
to  	to  	 TO	O
make  	make  	 VB	O
the  	the  	 DT	O
decision  	decision  	 NN	O
having  	having  	 VBG	O
in  	in  	 IN	O
mind  	mind  	 NN	O
the  	the  	 DT	O
best  	best  	 JJS	O
interest  	interest  	 NN	O
of  	of  	 IN	O
their  	their  	 PRP$	O
patients 	patients 	 NNS	O
.  	.  	 .	O
Last  	Last  	 JJ	O
but  	but  	 CC	O
not  	not  	 RB	O
least 	least 	 JJS	O
,  	,  	 ,	O
the  	the  	 DT	O
associated  	associated  	 JJ	O
health  	health  	 NN	O
economic  	economic  	 JJ	B-NP
burden  	burden  	 NN	I-NP
should  	should  	 MD	O
also  	also  	 RB	O
be  	be  	 VB	O
considered 	considered 	 VBN	O
.  	.  	 .	O
This  	This  	 DT	O
paper  	paper  	 NN	O
addresses  	addresses  	 VBZ	O
some  	some  	 DT	O
issues  	issues  	 NNS	O
related  	related  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
cetuximab  	cetuximab  	 NN	B-NP
and  	and  	 CC	O
bevacizumab  	bevacizumab  	 NN	B-NP
in  	in  	 IN	O
advanced  	advanced  	 JJ	O
NSCLC 	NSCLC 	 NNP	B-NP
.  	.  	 .	O
The  	The  	 DT	O
main  	main  	 JJ	O
controversial  	controversial  	 JJ	B-NP
aspects  	aspects  	 NNS	I-NP
regarding  	regarding  	 VBG	O
patient  	patient  	 JJ	O
selection 	selection 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
real  	real  	 JJ	O
benefit  	benefit  	 NN	O
of  	of  	 IN	O
therapy 	therapy 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
molecular  	molecular  	 JJ	O
and  	and  	 CC	O
clinical  	clinical  	 JJ	B-NP
predictors 	predictors 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
impact  	impact  	 NN	O
of  	of  	 IN	O
other  	other  	 JJ	O
independent  	independent  	 JJ	O
variables  	variables  	 NNS	O
are  	are  	 VBP	O
carefully  	carefully  	 RB	O
examined  	examined  	 VBN	O
and  	and  	 CC	O
presented 	presented 	 VBN	O
.  	.  	 .	O
Due  	Due  	 JJ	O
to  	to  	 TO	O
many  	many  	 JJ	O
unsolved  	unsolved  	 JJ	O
questions 	questions 	 NNS	O
,  	,  	 ,	O
no  	no  	 DT	O
definite  	definite  	 JJ	O
conclusions  	conclusions  	 NNS	O
can  	can  	 MD	O
be  	be  	 VB	O
supported 	supported 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
final  	final  	 JJ	B-NP
decision  	decision  	 NN	I-NP
about  	about  	 IN	O
the  	the  	 DT	O
optimal  	optimal  	 JJ	B-NP
use  	use  	 NN	I-NP
of  	of  	 IN	O
these  	these  	 DT	O
agents  	agents  	 NNS	O
is  	is  	 VBZ	O
left  	left  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
judgment  	judgment  	 NN	I-NP
of  	of  	 IN	O
each  	each  	 DT	O
treating  	treating  	 JJ	O
physician 	physician 	 NN	O
.  	.  	 .	O
